Tobacco Documents Online

1390 A.J. SANDFORD ET AL. RA, Fick RB. Independent mutations in the flanking sequence of the alphal-antitrypsin gene are associated with chronic obstructive airways disease. Dis Markers 1990; 8: 151-157. 66. Billingsley GD, Walter MA, Hammond GL, Cox DW. Physical mapping of four serpin genes: at-antit~psin, txl-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280 kb region on chro- mosome 14q32.1. AmJHura Genet 1993; 52: 343-353. 67. Cruickshank AM, Hansell DT, Bums HJG, Shenkin A. Effect of nutritional status on acute phase protein res- ponse to elective surgery. BrJSurg 1989; 76: 165-168. 68. Morgan K, Scobie G, Kalsheker N. The characterization of a mutation of the 3' flanking sequence of the a: antitrypsin gene commonly associated with chronic ob- structive airways disease. Eur J Clin Invest 1992; 22: 134-137. 69. Morgan K, Scobie G, Kalsheker NA. Point mutation in a 3' flanking sequence of the alphat-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence. Hum Mol Genet 1993; 2: 253-257. 70. Perlmutter DH, May LT, Sehgal PB. Intefferon-l~2/inter- leukin-6 modulates synthesis of txvantitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 1989; 84: 139-144. 71. Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G. The two C/EBP isoforms, IL-6 DBP/NF-IL-6 and C/EBP 5 NF-IL-6 [~ are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res 1993; 21: 289--294. 72. Buraczynska M, Sch6tt D, Hanzlik A J, H61tmarm B, Ulmer WT. Alphat-antitrypsin gene polymorphism rela- ted to.respiratory system disease. Klin Woschr 1987; 65: 538--541. 73. Kilpatrick L, Johnson JL, Nickbarg EB, et aL Inhibition of human neutrophil superoxide generation by t~l-anti- chymotrypsin. J Imraunol 1991; 146: 2388-2393. 74. Burnett D, McGillivray DH, Stockley RA. Evidence that alveolar macrophages can synthesize and secrete alphal-antichymotrypsin. Am Rev Respir Dis 1984; 129: 473-476. 75. Eriksson S, Lindmark B, Lilja H. Familial a~-antiehy- motrypsin deficiency. Acta MedScand 1986; 220: 447- 453. 76. Lindmark BE, Arborelius M, Eriksson SG. Pulmonary function in middle-aged women with heterozygous defi- ciency of the serine protease inhibitor alpha~-antichy- motrypsin. Am Rev Respir Dis 1990; 141: 884-888. 77. Lindmark B, Svenonius E, Edksson S. Heterozygous txl-antichymotrypsin and PiZ a~-antitrypsin deficiency: prevalence and clinical spectrum in asthmatic children. Allergy 1990; 45: 197-203. 78. Poller W, Faber J-B, Scholz S, et al. Mis-sense muta- tion of a:antichymotrypsin gene associated with chro- nic lung disease. Lancet 1992; 339: 1538. 79. Poller W, Faber $-P, Weidinger S, et al. A leucine-to- proline substitution causes a defective ctt-antichymotryp- sin allele associated with familial obstructive lung ~.sease. Genomics 1993; 17: 740-743. 80. Samilchuk EI, Chuchalin AG. Mis-sense mutation of a:antichymotrypsin gene and chronic lung disease. Lancet 1993; 342: 624. 81. Welch MJ, Tsui L-T, Boat TF, Beaudet AL. The Metabolic Basis of Inherited Disease. In: Scriver CL, Beaudel AL, Sly WS, Valle D, eds. New York, McGraw- Hill Inc., 1995; pp. 3799-3876. 82. Meindl RS. Hypothesis: a selective advantage for cys- tic fibrosis heterozygotes. Am J Phys Anthropol 1987; 74: 39-45. 83. Shier WT. Increased resistance to influenza as a poss~le source ofheterozygote advantage in cystic fibrosis. Med Hypotheses 1979; 5: 661-667. 84. Quinton PM. Fluid and Electrolyte Abnormalities in Exocrine Glands in Cystic Fibrosis. In: Quinton PM, Martinez R J, Hopfer U, eds. San Francisco, San Francisco Press, 1982; pp. 53-76. 85. Gabriel SE, Brigman KN, Koiler BH, Boucher RC,. Stutts MJ. Cystic fibrosis resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994; 266:1 107-109. 86. Anderson CM, Freeman M, Allan J, Hubbard L. Observa-, tions on: i) sweat sodium levels in relation to chronic respiratory disease in adults; and ii) the incidence of respiratory and other disease in parents and siblings of patients with fibroeystie disease of the pancreas. Med J Aust 1962; 1: 965-969. 87. Orzaleski MM, Kohner D, Cook CD, Shwachman H. Anamnesis: sweat electrolyte and pulmonary function studies in parents of patients with cystic fibrosis of the pancreas. Acta Paediatr 1963; 52: 267-276. 88. Batten J, Muir D, Simon G, Cedric C. The prevalence of respiratory disease in heterozygotes for the gene for fibrocystie disease of the pancreas. Lancet 1963; i: 1348-1350. 89. Hallett W'Y, Knudson AG, Massey FJ. Absence of detri- mental effect of the carrier state for the cystic fibrosis gene. Am Rev Respir Dis 1965; 90: 714-724. 90. Davies PB. Autonomic and airway reactivity in oblig- ate heterozygotes for cystic fibrosis. Am Rev Respir Dis 1984; 129:911-914. 91. Davis PB, Vargo K. Pulmonary abnormalities in oblig- ate heterozygotes for cystic fibrosis. Thorax 1987; 42: 120-125. 92. Kerem B-S, Rommens JM, Buchanan JA, et al. Identifi- cation of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080. 93. Poller W, Faber J-P, Scholtz S, Olek K, Mtiller K-M. Sequence analysis of the cystic fibrosis gene in patients with disseminated bronchiectatic lung disease. Klin Wschr 1991; 69: 657-663. 94. Dumur V, Lafitte J-J, Gervais R, et al. Abnormal distri- bution of cystic fibrosis AF508 allele in adults with chro- nic bronchial hypersecretion. Lancet 1990; 335: 1340. 95. Gervals R, Lafitte J-J, Dumur V, et al. Sweat chloride and AF508 mutation in chronic bronchitis or bronchiec- tasis. Lancet 1993; 342: 997. 96. Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takisima T. AF508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis 1992; 146: 781-783. 97. Artlich A, Boysen A, Bunge S, Entzian P, Schlaak M, Schwinger E. Common CFrR mutations are not likely to predispose to chronic bronchitis in Northern Germany. Hum Genet 1995; 95: 226-228. 98. Entzian P, Mtiller E, Boysen A, Artlich A, Schwinger E, Schlaak M. Frequency of common cystic fibrosis gene mutations in chronic bronchitis patients. Scand J Lab Invest 1995; 55: 263-266. 99. Pignatti PF, Bombied C, Marigo C, Benetazzo M, Luisetti M. Increased incidence of cystic fibrosis gene muta- tions in adults with disseminated bronchiectasis. Hum Mol Genet 1995; 4: 635-636. 100. Pignatti PF, Bombieri C, Benetazzo M, et al. CIzTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996; 58: 889-892. I01. Gasparini P, Savoia A, Luisetti M, Peona V, Pignatti PF. The cystic fibrosis gene is not likely to be involved in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1990; 2: 297-299. 102. Kew R.R, Webster RO. Gc-globulin (vitamin D-binding

GENETICS OF COPD 1391 protein) enhances the neutrophil chemotactic activity of CSa and C5a des Arg../Clin Invest 1988; 82: 36~-369. 103. Yamamoto N, Homma S. Vitamin D-binding protein (group-specific component) is a precursor for the mac- rophage-activating signal factor from lysophosphatidyl- choline-treated lymphocytes. Proc Natl Acad Sci USA 1991; 88: 8539-8543. 104. Horue SL, Cockcroft DW, Dosman JA. Possible pro- tective effect against chronic obstructive airways dis- ease by the GC 2 allele. Hum Hered 1990; 40: 173-176. 105. Kauffmann F, Kleisbauer J-P, Cambon-de-Mouzon A, et al. Genetic markers in chronic airflow limitation: a genetic epidemiologic study. Am Rev Respir Dis 1983; 127: 263-269. I06. White R, Janoff A, Godfrey HP. Secretion of alphaz- macroglobulin by alveolar macrophages. Lung 1980; 158: 9-14. I07. Mosher DF, Wing WA. Synthesis and secretion of c~a- macroglobulin by cultured human fibroblasts. J Exp Med 1976; 143: 462-467. I08. BShm N, Shah I, Totovic" V, Karitzky D. Combined at-antitrypsin and c~2-macroglobulin deficiency syn- drome: fight microscopic evidence of coIlagenolytic, elastolytic and myolytic tissue lesions. Path Res Prac 1980; 168: 17-35. I09. Burnett D, Stockley RA. Serum and sputum a2-macro- globulin in patients with chronic obstructive airways disease. Thorax 1981; 36: 512-516. I I0. Brissenden JE, Cox DW. AIpha2-macroglobufin in pati- ents with obstructive lung disease, with and without a: antitrypsin deficiency. Clin Chim Acta 1983; 128: 241-248. 111. Gain'or PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in at-antitrypsin deft- cien~y. Scand J Clin Lab Invest 1967; 19: 205-208. 112. Bergqvist D, Nilsson IM. Hereditary ec2-macroglobufin deficiency. Scand ~ Haematol 1979; 23: 433-436. 113. Stenbjerg S. Inherited alpha~-macroglobulin deficiency. Thrombosis Res 1981; 22: 491-495. 114. Poller W, Faber J-P, Klobeck G, Olek K. Cloning of the human ~-macroglobulin gene and detection of muta- tions in two functional domains: the bait region and the thiolester site. Hum Genet 1992; 88: 313-319. 115. Poller W, Barth J, Voss B. Detection of an alteration of the e~-macroglobulin gene in a patient with chronic lung disease and serum (~,z-macroglobufin deficiency. Hura Genet 1989; 83: 93-96. 116. Drakoulis N, Cascorbi I, BrockmSller J, Gross CR, Roots I. Polymorphisms in the human CYPIA1 gene as sus- ceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the Y-flanking region. Clin Invest 1994; 72: 240-248. 117. Cantlay AM, Lamb D, Gillooly M, et al. Association between the CYP1A1 gene polymorphism and suscepti- bility to emphysema and lung cancer. J Clin Pathol: Mol Pathol 1995; 48: M210-214. 118. Cohen BH, Ball WC, Brashears S, et aL Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol 1977; 105: 223-232. 119. Beatty TH, Menkes HA, Cohen BH, Newill CA. Risk factors associated with longitudinal change in pulmonary function. Am Rev Respir Dis 1984; 129: 660-667. 120. Krzyzanowski M, Jedi3'chowski W, Wysocki M. Factors associated with the change in ventilatory function and the development of chronic obstructive pulmonary dis- ease in a 13 year follow-up of the Cracow study. Am Rev Respir Dis 1986; 134: 1011-1019. 121. Higgins MW, Keller JB, Becker M, et al. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982; 125: 144-151. 122. Vestbo J, Hein HO, Suadicani P, SOrensen H, Gyntelberg F. Genetic markers for chronic bronchitis and peak expiratory expiratory flow in the Copenhagen Male Study. Dan Med Bull 1993; 40: 378-380. 123. Cohen BH, Bias WB, Chase GA, et al. Is ABH non- secretor stares a risk factor for obstructive lung disease? Am J Epidetniol 1980; 111: 285-291. 124. Haines AP, Imeson JD, Meade TW. ABH secretor sta- tus and pulmonary function. Am J Epidemiol 1982; 115: 367-370. 125. Abboud RT, Yu P, Chan-Yeung M, Tan F. Lack of relationship between ABH secretor status and lung func- tion in pulp-mill workers. Am Rev Respir Dis 1982; 126: 1089-1091. 126. Home SL, Cockcroft DW, Lovegrove A, Dosman JA. ABO, Lewis and secretor status and relative incidence of airflow obstruction. Dis Markers 1985; 3: 55--62. 127. Kauffmann F, Frette C, Pham Q-T, Nafissi S, Bertrand J-P, Oriol R. Associations of blood group-related anti- gens to FEVI, wheezing and asthma. Am 3 Respir Crit Care Med 1996; 153: 76-82. 128. Raza MW, Blackwell CC, Molyneaux P, etaL Associa- tion between secretor status and respiratory viral illness. Br Med J 1991; 303: 815-818. 129. Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse pan- bronchiolitis. Am Rev Respir Dis 1990; 14l: 1459-1462. 130. Bj5rkander J, Bake B, Oxelius VA, Hanson 1.~. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N Engl J Med 1985; 313: 720- 724. 131. O'Keefe S, Gzel A, Drury R, Cullina M, Greally J, Finnegan P. Immunoglobulin G subclasses and spirom- etry in patients with chronic obstructive pulmonary dis- ease. Eur Respir J 1991; 4: 932-938. 132. Oxelius VA, Laurell AB, Lindquist B, et al. lgG sub- classes in selective IgA deficiency. N Engl J Med 1981; 304: 1476-1477. 133. Webb DR, Condemi JL Selective immunoglobulin A deficiency and chronic obstructive lung disease. Ann Intern Med 1974; 80: 618-621. Folz ILl, Peno-Green L, Crapo JD. Identification of a homozygous mis-sense mutation (Arg to Gly) in the crit- ical binding region of the human EC-SOD gene (SOD3) and its association with dramatically increased serum enzyme levels. Hum Mol Genet 1994; 3: 2251-2254. 135. SandstrSm J, Nilsson P, Karlsson K, Marklund SL. Tenfold increase in human plasma extracellular super- oxide dismutase content caused by a mutation in heparin- binding domain. JBiol Chem 1994; 268: 19163-19166. 136. Peno-Green L, Crapo JD, Folz RJ. Characterization of human serum extracellular superoxide dismutase vari= ants in normal and lung disease individuals. Am JRespir Crit Care Med 1995; 151: A167. 137. Sallenave J-M, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/Elafin) in human airway epithelial airway cells by cytokines .-and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994; 1 I: 733-741. 138. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithe- lial cells. J Clin Invest 1991; 87: 2207-2215. 139. Liidecke B, Poller W, Olek K, Bartholom~ K. Sequence variant of the human cathepsin G gene. Hum Genet 1993; 91: 83-84. 140. Weiss ST, Segal MR, Sparrow D, Wager C. Relation of FEVI and peripheral blood leukocyte count to total mortality: the normative aging study. Am J Epidemiol 1995; 142: 493-498. 134.